Keywords: GlaxoSmithKline, Tolerx, BTG, Otelixizumab, Type 1 diabetes

GlaxoSmithKline/Tolerx diabetes drug otelixizumab disappoints in Ph III study

Article | 14 March 2011

Print This

There was bad news for privately-held US biotech Tolerx and partner UK pharma giant GlaxoSmithKline (LSE: GSK) on Friday, when ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in